This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

This study has been completed.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries Identifier:
First received: March 12, 2013
Last updated: February 26, 2016
Last verified: February 2016
The primary objective of this study is to evaluate the clinical effect of TV-1106.

Condition Intervention Phase
Growth Hormone Deficiency Drug: TV-1106 Drug: Recombinant human growth hormone Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 64-Week (12-week Core Phase and 52-week Safety Extension), Phase II, Multicenter, Randomized, Open Label Study to Evaluate the Safety, Tolerability and Efficacy of Weekly TV-1106 in Adults With Growth Hormone Deficiency

Resource links provided by NLM:

Further study details as provided by Teva Pharmaceutical Industries:

Primary Outcome Measures:
  • Insulin-like growth factor I (IGF-I) concentration change from baseline [ Time Frame: Baseline to Week 12 ]

Secondary Outcome Measures:
  • Percentage of patients treated with TV1106 who return to pre-treatment IGF-1 SDS [ Time Frame: Baseline to Week 12 ]
  • Safety Parameters [ Time Frame: 78 weeks ]
    The safety of TV-1106 will be assessed throughout the study by evaluating adverse events,concomitant medication usage, physical examinations including urinalysis and body weight, vital sign measurements, clinical laboratory test results and hormone levels, electrocardiograms (ECGs), and immunogenicity.

Enrollment: 52
Study Start Date: March 2013
Study Completion Date: July 2015
Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: TV-1106
Titration dose levels of TV-1106
Drug: TV-1106
Active Comparator: recombinant human growth hormone
Daily subcutaneous dose
Drug: Recombinant human growth hormone
Subcutaneous once daily


Ages Eligible for Study:   23 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient agrees to provide written informed consent and to comply with the study protocol after reading the informed consent and discussing the study with the investigator.
  • Males and females between 23 and 65 years of age must have a confirmed diagnosis of adult GHD, either adult onset (AO) GHD due to hypothalamic-pituitary disease or childhood onset (CO) GHD that is either idiopathic or due to hypothalamic-pituitary disease or due to genetic causes.
  • Diagnosis of GH deficiency must be confirmed by documented (medical records) diagnostic testing.
  • Patients should have been treated with a stable dose of daily rhGH for at least 3 months prior to screening.
  • Other criteria apply.

Exclusion Criteria:

  • Patients with history or clinical evidence of active or chronic diseases that could confound results of the study or put the subject at undue risk as determined by the investigator.
  • Patients with known active malignancy
  • Patients with history of malignancy other than intracranial tumor causing GHD (excluding surgically cured basal cell or squamous cell cancer of the skin with documented 6 month remission)
  • Patients with evidence of pituitary adenoma or other intracranial tumor within 12 months of enrollment, which is on day 0 (baseline, Visit 3)
  • Patients without magnetic resonance imaging (MRI) or computerized tomography (CT) data to document tumor stability within the 12 months prior to enrollment, which is on day 0 (baseline, Visit 3)
  • Presence of Prader-Willi syndrome, Turner's syndrome, untreated adrenal insufficiency, active acromegaly in the past 5 years, or active Cushing's syndrome in the past 1 year.
  • Other criteria apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01811576

United States, Oregon
Teva Investigational Site 10564
Portland, Oregon, United States
Czech Republic
Teva Investigational Site 54051
Olomouc, Czech Republic
Teva Investigational Site 32237
Munich, Germany
Teva Investigational Site 32238
Munich, Germany
Teva Investigational Site 63044
Athens, Greece
Teva Investigational Site 63045
Athens, Greece
Teva Investigational Site 51056
Budapest, Hungary
Teva Investigational Site 51061
Gyor, Hungary
Teva Investigational Site 51059
Pecs, Hungary
Teva Investigational Site 51057
Szeged, Hungary
Teva Investigational Site 51058
Szolnok, Hungary
Teva Investigational Site 80032
Petach Tikva, Israel
Teva Investigational Site 61029
Belgrade, Serbia
Teva Investigational Site 62017
Bratislava, Slovakia
Teva Investigational Site 62022
Bratislava, Slovakia
Teva Investigational Site 62016
Lubochna, Slovakia
Teva Investigational Site 64016
Ljubljana, Slovenia
Sponsors and Collaborators
Teva Pharmaceutical Industries
  More Information

Responsible Party: Teva Pharmaceutical Industries Identifier: NCT01811576     History of Changes
Other Study ID Numbers: TV1106-GHD-201
2012-004975-37 ( EudraCT Number )
Study First Received: March 12, 2013
Last Updated: February 26, 2016

Keywords provided by Teva Pharmaceutical Industries:
Growth hormone deficiency
Insulin-like growth factor I (IGF-I)

Additional relevant MeSH terms:
Dwarfism, Pituitary
Endocrine System Diseases
Bone Diseases, Developmental
Bone Diseases
Musculoskeletal Diseases
Bone Diseases, Endocrine
Pituitary Diseases
Hypothalamic Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs processed this record on September 19, 2017